Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report

MeSH terms

• Adenocarcinoma / drug therapy
• Adenocarcinoma / genetics
• Adenocarcinoma / pathology
• Adenocarcinoma, Bronchiolo-Alveolar / drug therapy
• Adenocarcinoma, Bronchiolo-Alveolar / genetics
• Adenocarcinoma, Bronchiolo-Alveolar / pathology
• Adult
• Aged
• Antineoplastic Agents / therapeutic use*
• Benzenesulfonates / therapeutic use*
• Carcinoma, Large Cell / drug therapy
• Carcinoma, Large Cell / genetics
• Carcinoma, Large Cell / pathology
• Carcinoma, Non-Small-Cell Lung / drug therapy*
• Carcinoma, Non-Small-Cell Lung / genetics
• Carcinoma, Non-Small-Cell Lung / pathology
• Carcinoma, Squamous Cell / drug therapy
• Carcinoma, Squamous Cell / genetics
• Carcinoma, Squamous Cell / pathology
• Female
• Humans
• Lung Neoplasms / drug therapy*
• Lung Neoplasms / genetics
• Lung Neoplasms / pathology
• Male
• Middle Aged
• Mutation / genetics*
• Neoplasm Staging
• Niacinamide / analogs & derivatives
• Phenylurea Compounds
• Proto-Oncogene Proteins / genetics*
• Proto-Oncogene Proteins p21(ras)
• Pyridines / therapeutic use*
• Sorafenib
• Survival Rate
• Treatment Outcome
• ras Proteins / genetics*